SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 ( SGLT1 ) inhibitor, with IC 50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > SGLT
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.